文献速递心力衰竭与心肌病

髓源性抑制细胞在心力衰竭中的心脏保护作用

Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure.
PubMed 文献 · Circulation · 2018-02-01

该研究在心力衰竭患者及压力负荷诱导的小鼠心衰模型中检测髓源性抑制细胞(MDSC)的变化,发现MDSC比例升高且与疾病严重程度正相关,并通过白介素-10和一氧化氮发挥抗炎及抗心肌肥厚作用;药物清除MDSC加重心衰,而过继转移或雷帕霉素扩增MDSC可改善心衰。

要点

  • 心衰患者外周血HLA-DR-CD33+CD11b+ MDSC比例升高,与病情严重程度及炎症因子水平正相关。
  • 清除MDSC加重压力负荷诱导的小鼠心脏重构和炎症,过继转移MDSC则改善心衰。
  • 雷帕霉素通过扩增内源性MDSC改善心衰,MDSC清除可阻断其获益。

核心结论

  • MDSC通过白介素-10和一氧化氮介导抗炎及抗心肌肥厚效应,在心力衰竭中发挥心脏保护作用。
  • 靶向MDSC的药理学策略(如雷帕霉素)可能是心力衰竭的潜在治疗方法。

研究设计与样本

  • 研究检测了心力衰竭患者及异丙肾上腺素或横向主动脉缩窄(TAC)诱导的小鼠心衰模型中MDSC的比例。
  • 通过5-氟尿嘧啶(50 mg/kg)或吉西他滨(120 mg/kg)清除MDSC、过继转移纯化MDSC、或雷帕霉素(2 mg·kg-1·d-1)增强内源性MDSC,观察对心衰的影响。

主要发现

  • 心衰患者血液中HLA-DR-CD33+CD11b+ MDSC比例显著增加,与疾病严重程度及血浆白介素-6、白介素-10、转化生长因子-β水平正相关。
  • 心衰患者来源的MDSC抑制T细胞增殖和干扰素-γ分泌。
  • 药物清除MDSC显著加重异丙肾上腺素和TAC诱导的病理性心脏重构和炎症,而过继转移MDSC显著挽救心衰。
  • 雷帕霉素通过抑制MDSC分化增加内源性MDSC,改善心衰,但MDSC清除大多阻断雷帕霉素的获益。
  • 中和白介素-10削弱单核细胞型MDSC和粒细胞型MDSC的抗炎及抗肥厚效应,一氧化氮抑制剂仅部分阻断单核细胞型MDSC的抗肥厚效应。

临床怎么用

  • 心衰患者MDSC比例升高且与病情严重程度相关,提示其可能作为炎症相关生物标志物。
  • 雷帕霉素扩增MDSC并改善心衰的临床前证据支持进一步探索靶向MDSC的治疗策略。

局限性

  • 研究主要基于小鼠心衰模型和有限的患者样本,MDSC在人类心衰中的确切作用仍需更大规模临床研究验证。
  • MDSC的异质性及不同亚型(单核细胞型与粒细胞型)的具体贡献机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that expand in cancer, inflammation, and infection and negatively regulate inflammation and the immune response. Heart failure (HF) is a complex clinical syndrome wherein inflammation induction and incomplete resolution can potentially contribute to HF development and progression. However, the role of MDSCs in HF remains unclear. METHODS: The percentage of MDSCs in patients with HF and in mice with pressure overload-induced HF using isoproterenol infusion or transverse aortic constriction (TAC) was detected by flow cytometry. The effects of MDSCs on isoproterenol- or TAC-induced HF were observed on depleting MDSCs with 5-fluorouracil (50 mg/kg) or gemcitabine (120 mg/kg), transferring purified MDSCs, or enhancing endogenous MDSCs with rapamycin (2 mg·kg-1·d-1). Hypertrophic markers and inflammatory factors were detected by ELISA, real-time polymerase chain reaction, or Western blot. Cardiac functions were determined by echocardiography and hemodynamic analysis. RESULTS: The percentage of human leukocyte antigen-D-related (HLA-DR)-CD33+CD11b+ MDSCs in the blood of patients with HF was significantly increased and positively correlated with disease severity and increased plasma levels of cytokines, including interleukin-6, interleukin-10, and transforming growth factor-β. Furthermore, MDSCs derived from patients with HF inhibited T-cell proliferation and interferon-γ secretion. Similar results were observed in TAC- and isoproterenol-induced HF in mice. Pharmaceutical depletion of MDSCs significantly exacerbated isoproterenol- and TAC-induced pathological cardiac remodeling and inflammation, whereas adoptive transfer of MDSCs prominently rescued isoproterenol- and TAC-induced HF. Consistently, administration of rapamycin significantly increased endogenous MDSCs by suppressing their differentiation and improved isoproterenol- and TAC-induced HF, but MDSC depletion mostly blocked beneficial rapamycin-mediated effects. Mechanistically, MDSC-secreted molecules suppressed isoproterenol-induced hypertrophy and proinflammatory gene expression in cardiomyocytes in a coculture system. Neutralization of interleukin-10 blunted both monocytic MDSC- and granulocytic MDSC-mediated anti-inflammatory and antihypertrophic effects, but treatment with a nitric oxide inhibitor only partially blocked the antihypertrophic effect of monocytic MDSCs. CONCLUSIONS: Our findings revealed a cardioprotective role of MDSCs in HF by their antihypertrophic effects on cardiomyocytes and anti-inflammatory effects through interleukin-10 and nitric oxide. Pharmacological targeting of MDSCs by rapamycin constitutes a promising therapeutic strategy for HF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhou L, Miao K, Yin B, et al. Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure. Circulation. 2018. PMID: 29437117. doi:10.1161/CIRCULATIONAHA.117.030811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。